EUVIMEDEUVIMED entdecken
Crossref

Plasma Ceramides Predict All-Cause and Cause-Specific Mortality in Individuals With Type 2 Diabetes

Sylvia Liu, Wai Kin Tham, Janus Lee, Keven Ang, Huili Zheng, Clara Chan, Resham L Gurung, Subramaniam Tavintharan, Chee Fang Sum, Markus R Wenk, Federico Torta, Jian-Jun Liu und 1 weitere

The Journal of Clinical Endocrinology & Metabolism · 22.04.2025 · 110 (5) · 1497-1504

DOI: 10.1210/clinem/dgae388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 08.06.2024. Verfasst von Sylvia Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Republic of Singapore 768828. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Ceramides, Cardiovascular Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Singapore National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The Cardiovascular Event Risk Test (CERT1) score derived from plasma ceramides has been applied clinically for cardiovascular risk assessment.

Objective

To study whether plasma ceramides predict risk of mortality in patients with type 2 diabetes.

Methods

In a prospective study that included 1903 outpatients with type 2 diabetes in a regional hospital and a primary care facility in Singapore, plasma ceramides (d18:1/16:0, d18:1/18:0, d18:1/24:0, d18:1/24:1) were measured by mass spectrometry and CERT1 score was calculated accordingly. Main outcomes were all-cause and cause-specific mortality.

Results

During a median of 9.3 years of follow-up, 252 death events were identified. Compared to those with low score (≤ 2), participants with a high CERT1 score (≥ 7) had 1.86-fold (95% CI, 1.30-3.65) increased risk for all-cause death after adjustment for cardiorenal risk factors, including estimated glomerular filtration rate and albuminuria. As continuous variable, 1-unit increment in CERT1 was associated with 8% increased risk for all-cause death (adjusted hazard ratio [HR] 1.08 [1.04-1.13]). Adding CERT1 onto Risk Equations for Complications Of type 2 Diabetes (RECODe) mortality risk engine significantly improved prediction of 10-year risk of all-cause death (area under the curve, 0.810 to 0.823, delta 0.013 [0.005-0.022]). The association between CERT1 and noncardiovascular death remained significant (adjusted HR 2.12 [1.32-3.42]), whereas its association with cardiovascular death became nonsignificant after adjustment for kidney measurements (adjusted HR 1.41 [0.78-2.56]).

Conclusion

CERT1 score predicts mortality risk independent of clinical cardiorenal risk factors. Further studies are warranted to elucidate the mechanistic linkage between ceramide and mortality, especially noncardiovascular mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2CeramidesCardiovascular DiseasesHumansFemaleMaleMiddle AgedAgedProspective StudiesCause of DeathPrognosisSingaporeFollow-Up StudiesRisk AssessmentRisk FactorsBiomarkersPredictive Value of Tests

Stichwörter der Autor:innen

CERT1 ceramide scoreall-cause deathcause-specific deathceramiderisk prediction

Substanzen

CeramidesBiomarkers

Autor:innen und Institutionen

  • Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Republic of Singapore 768828.
  • Precision Medicine Translational Research Programme and Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore 119077.
  • Singapore Lipidomics Incubator, Life Sciences Institute, National University of Singapore, Singapore, Republic of Singapore 119077.
  • DUKE-NUS Medical School, Cardiovascular and Metabolic Disorders Signature Research Program, Singapore, Republic of Singapore 169857.
  • Diabetes Centre, Admiralty Medical Centre, Singapore, Republic of Singapore 730676.
  • Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Republic of Singapore 308232.

ORCID-Profile: Su Chi Lim

Förderung

  • Singapore National Medical Research Council

Zitieren

APA

Liu, S., Tham, W. K., Lee, J., Ang, K., Zheng, H., Chan, C., Gurung, R. L., Tavintharan, S., Sum, C. F., Wenk, M. R., Torta, F., Liu, J. J., & Lim, S. C. (2025). Plasma Ceramides Predict All-Cause and Cause-Specific Mortality in Individuals With Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 110(5), 1497-1504. https://doi.org/10.1210/clinem/dgae388

Vancouver

Liu S, Tham WK, Lee J, Ang K, Zheng H, Chan C, et al. Plasma Ceramides Predict All-Cause and Cause-Specific Mortality in Individuals With Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2025;110(5):1497-1504. doi:10.1210/clinem/dgae388

BibTeX
@article{Liu2025,
  author = {Liu, Sylvia and Tham, Wai Kin and Lee, Janus and Ang, Keven and Zheng, Huili and Chan, Clara and Gurung, Resham L and Tavintharan, Subramaniam and Sum, Chee Fang and Wenk, Markus R and Torta, Federico and Liu, Jian-Jun and Lim, Su Chi},
  title = {Plasma Ceramides Predict All-Cause and Cause-Specific Mortality in Individuals With Type 2 Diabetes},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {5},
  pages = {1497--1504},
  doi = {10.1210/clinem/dgae388}
}
Kostenlos starten →